Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

VDPHL01 is discussed as a potential replacement for DHT blockers, with comparisons to minoxidil. Users express skepticism about its effectiveness without addressing DHT, suggesting it may only slow hair loss rather than stop it.

A 49-year-old is using minoxidil, finasteride, and supplement chews for hair growth, experiencing thick growth except on the top, and seeking advice on improving density. Suggestions include continuing treatment, considering additional options like oral minoxidil, ketoconazole shampoo, dermapen, and possibly a hair transplant, though cost is a concern.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

The user is using Minoxidil, finasteride, Nizoral, and dermarolling for hair loss but is not seeing results. They are considering trying a product called "capilia longa" for beard growth and are questioning its effectiveness.

The conversation discusses hair loss treatments, focusing on reducing scalp itching and dandruff using natural shampoos, witch hazel, and apple cider vinegar. The user also mentions using finasteride and observing potential regrowth, though it's difficult to confirm.

The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

Creatine may increase DHT, potentially affecting hair loss, but opinions vary. Users discuss using finasteride and alternatives like plant protein to manage hair loss.

Clascoterone, a topical anti-androgen, shows promise for treating female pattern hair loss without systemic side effects, offering a potential alternative to minoxidil. It could also benefit men who experience side effects from finasteride.

The conversation critiques the influence of "Clavicular" on young men regarding hair loss treatments, highlighting the dangers of following unscientific advice and the rise of body dysmorphia. It emphasizes the importance of safe, medically advised treatments like minoxidil, finasteride, and dutasteride, while warning against reckless experimentation and early surgeries.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.

The user experienced significant hair shedding after starting a caffeine shampoo called Alpecin, despite being on finasteride and switching to dutasteride. The doctor suggested the shedding might be due to new hair growth, while others speculated it could be from switching medications or the shampoo's ineffectiveness.

The conversation humorously discusses hair regrowth using PP405, with jokes about side effects and secret hair transplants. The user claims no side effects except craving cheese.

Chlorine dioxide was discussed as a potential hair growth treatment, with a method involving spraying it on the scalp and covering it with a cap. Concerns were raised about its safety, comparing it to bleach.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

The user experienced hair regrowth using a chewable combination of oral minoxidil and finasteride without side effects, unlike when taken separately. The treatment is from Hims, and the user is satisfied with the progress, especially on the crown.

Haircafe is generally trusted for hair loss information, particularly for his evidence-based approach and recommendations of finasteride, dutasteride, and minoxidil. While some users appreciate his scientific focus and lack of product promotion, others criticize his dismissal of anecdotal evidence and certain biases.

Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.

The conversation is about a user interested in participating in hair cloning clinical trials due to their fine hair and previous positive experience with clinical trials. They are seeking information on how to volunteer for such trials.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.